Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  GlaxoSmithKline    GSK   GB0009252882

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed London Stock Exchange
10/10/2017 10/11/2017 10/12/2017 10/13/2017 10/16/2017 Date
1515.5(c) 1517(c) 1527.5(c) 1516(c) 1519(c) Last
5 753 843 4 684 221 5 528 626 5 529 456 8 384 497 Volume
-0.49% +0.10% +0.69% -0.75% +0.20% Change
More quotes
Financials ( GBP)
Sales 2017 30 193 M
EBIT 2017 8 338 M
Net income 2017 4 180 M
Debt 2017 13 917 M
Yield 2017 5,28%
Sales 2018 30 870 M
EBIT 2018 8 640 M
Net income 2018 4 625 M
Debt 2018 13 297 M
Yield 2018 5,31%
P/E ratio 2017 19,78
P/E ratio 2018 15,87
EV / Sales2017 2,93x
EV / Sales2018 2,85x
Capitalization 74 566 M
More Financials
Company
‘GlaxoSmithKline Plc is a global healthcare company which engages in developing, manufacturing, and marketing of pharmaceutical products including vaccines, over the counter medicines and health-related consumer products.It operates through the following segments: Pharmaceuticals, Pharmaceuticals... 
Sector
Pharmaceuticals
Calendar
10/25 | 01:00pmEarnings Release
More about the company
Surperformance© ratings of GlaxoSmithKline
Trading Rating : Investor Rating :
More Ratings
Latest news on GLAXOSMITHKLINE
10/13 GLAXOSMITHKLINE : shingles vaccine gets approval in Canada
10/13 GLAXOSMITHKLINE : GSK announces first approval of Shingrix in Canada
10/13 GLAXOSMITHKLINE : GSK first approval of Shingrix in Canada
10/12 THIN FILM ELECTRONICS : Thinfilm and GlaxoSmithKline Bring NFC Technology to Lea..
10/12 GLAXOSMITHKLINE : Chinas C-Bridge hires ex-GlaxoSmithKline executive for U.S. in..
10/12 GLAXOSMITHKLINE : Investigators from GlaxoSmithKline plc Report New Data on Phar..
10/12 GLAXOSMITHKLINE : Researchers from GlaxoSmithKline plc Report Recent Findings in..
10/11DJMERCK AND : Ebola Vaccines Show Promise in New Study
10/05 RESEARCHERS AT GLAXOSMITHKLINE PLC T : drug discovery insight, challenges and...
10/05 GLAXOSMITHKLINE : Findings from GlaxoSmithKline plc Broaden Understanding of And..
More news
Sector news : Pharmaceuticals - NEC
03:29p ASTRAZENECA : Pharma and medtech industries prepare for hard Brexit
10:45a CONVATEC : slashes revenue growth outlook, shares slump
10/14DJBAYER : Unloads Assets to Aid Deal -- WSJ
10/13 ASPEN PHARMACARE : UK anti-trust regulator investigates South Africa's Aspen Pha..
10/13DJROCHE : Gets CHMP Recommendation for Lung Cancer Treatment Alecensa
More sector news : Pharmaceuticals - NEC
4-Traders Strategies on GLAXOSMITHKLINE 
GLAXOSMITHKLINE  - 2015
This could be the time to buy
BUY
GLAXOSMITHKLINE - 2014
Bearish signal below GBp 1415
SELL
More Strategies
Latest Tweets
05:44pCetera Investment Advisers Has $1.12 Million Position in GlaxoSmithKline PLC .. 
08:57aGlaxoSmithKline plc's PT raised by Jefferies Group LLC to GBX 1,700. buy rati.. 
10/15Oak Associates Ltd. OH Purchases 28,220 Shares of GlaxoSmithKline PLC $GSK  
10/15GlaxoSmithKline's shingles vaccine gets approval in Canada  
10/14Innoviva, Inc. $INVA Sees Unusually-High Trading Volume  
More tweets
Qtime:330
News from SeekingAlpha
11:21a SANOFI : Upward Trajectory In 2017
10/13 Glaxo shingles vaccine OK'd in Canada
10/10 California enacts law aimed at corralling high drug prices
10/09 Agenus Loads Up Impressive New Pipeline
10/09 China to accept out-of-country trial data to speed up drug approvals
Chart GLAXOSMITHKLINE
Duration : Period :
GlaxoSmithKline Technical Analysis Chart | GSK | GB0009252882 | 4-Traders
Technical analysis trends GLAXOSMITHKLINE
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 30
Average target price 17,2  GBP
Spread / Average Target 13%
EPS Revisions
Managers
NameTitle
Emma Walmsley Chief Executive Officer & Executive Director
Philip Roy Hampton Non-Executive Chairman
Simon Dingemans Chief Financial Officer & Executive Director
Patrick J. T. Vallance Executive Director, President-R&D
Karenann K. Terrell Chief Technology Officer
Sector and Competitors
1st jan.Capitalization (M$)
GLAXOSMITHKLINE-2.94%99 045
JOHNSON & JOHNSON18.42%366 178
NOVARTIS13.23%225 160
ROCHE HOLDING LTD.5.20%216 764
PFIZER11.88%216 409
MERCK AND COMPANY7.68%172 887